Elan Corporation (ELN)
News
| May 27 | $ELN http://stks.co/4008 Looks really strong here, broke and closed above 50 day MA. Strong volume. by ACInvestorBlog |
| May 26 | $ELN Has a market cap of $8B, how much upside here. 25-50%? by MaddStocks |
| May 25 | Health Care Sector Wrap Fox Business |
| May 25 | IV30(TM) GAINER $ELN +17.65% $IOC +15.89% $CVLT +7.71% $END +5.31% by livevol_pro |
| May 25 | $ELN my guess is you see a nice runup ahead of that Bapineuzumab data. go long, but sell a good chunk of your position ahead of the release by tickertutor |
| May 25 | IV30(TM) GAINER $ELN +20.09% $MRX +10.41% $IOC +5.84% $CALL +5.7% by livevol_pro |
| May 25 | Elan Corporation plc, Quest Software Among Stocks Up on High Volume Friday Fox Business |
| May 25 | $ELN gonna say you ride this thing up to 15.35... that is a huge technical hurdle right there. by tickertutor |
| May 25 | IV30(TM) GAINER $MRX +14.21% $ELN +11.33% by livevol_pro |
| May 25 | $ELN up on decent volume. by beckyhiu |
| May 18 | Billionaire Soros' Q1 High Conviction Buys In 2 Growth Stocks, Other Buys And Sells |
| May 18 | Revenues Skyrocket at Merged Alkermes |
| May 18 | Data on Elan & Biogen's Tysabri |
Profile
Exchange: NYSE Sector: Healthcare Industry: Drug Delivery & Accessories
Elan is a neuroscience-focused biotechnology company headquartered in Dublin, Ireland. The company is organized into two business units: BioNeurology and Elan Drug Technologies. Elan's work includes research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease and autoimmune diseases, including multiple sclerosis. It was incorporated as a private limited company in December 1969 and became a public limited company in January 1984.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Elan Corporation is up 52.29% over the last year vs S&P 500 Total Return up 1.18%, Alkermes down 11.12%, and Biogen Idec up 41.14%.
- ELN Total Returns
- ^SPXTR Total Returns
- ALKS Total Returns
- BIIB Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these ELN related companies
Pro Strategies Featuring ELN
Did Elan Corporation make it into our Pro Portfolio Strategies?
ELN Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other ELN Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ELN | 14.30 | +1.11 | +8.42% | 8.428B |
| ELLO | 5.65 | -0.20 | -3.42% | 60.91M |
| ELGX | 14.27 | +0.19 | +1.35% | 830.23M |
| EL | 54.96 | -0.13 | -0.24% | 21.31B |
| EKH | 50.95 | +0.00 | +0.00% | |
| EJ | 5.59 | +0.14 | +2.57% | 461.01M |
| EIX | 45.00 | +0.15 | +0.33% | 14.66B |
| EIRL | 20.45 | +0.06 | +0.29% | |
| EIP | 14.78 | +0.01 | +0.07% | |
| EFII | 15.44 | -0.12 | -0.77% | 709.62M |
